Japan PM Ishiba to announce resignation by August end – Mainichi
On Wednesday, BTIG analyst Ryan Zimmerman adjusted the price target for Spectral AI (NASDAQ:MDAI) shares to $2 from the previous $3 while maintaining a Buy rating on the stock. This adjustment comes after the company’s first-quarter results for 2025, which revealed a higher share count than before. According to InvestingPro data, the stock has shown significant momentum with a 22.41% return over the past week, despite trading well below its 52-week high of $3.25.
Spectral AI reported revenue of $6.7 million, surpassing BTIG’s estimates of $4.6 million. The earnings per share (EPS) were $0.12, significantly higher than the estimated loss of $0.19 per share, owing to a change in warrant liability value. Despite better than expected financial results, the company is taking measures to reduce its operating expenses in order to conserve cash, a move that BTIG views as prudent. InvestingPro analysis indicates the company’s current financial health score is "FAIR," though its current ratio of 0.57 suggests potential liquidity challenges.
Management at Spectral AI has reiterated its full-year 2025 revenue guidance from the Biomedical Advanced Research and Development Authority (BARDA), expecting approximately $21.5 million, which marks a 27.3% decrease year-over-year. The company is on track with its regulatory and commercial objectives, including the anticipated submission of their DeepView product to the FDA by the end of the second quarter of 2025, with approval expected in early 2026. InvestingPro subscribers can access additional insights through the comprehensive Pro Research Report, which provides detailed analysis of the company’s growth prospects and financial health metrics.
Spectral AI’s cash position has seen an improvement, now standing at $14.1 million, which includes $8.5 million in new debt. These funds, along with the reduced operational spending, are expected to enable the company to generate commercial revenue with the existing cash on hand.
Zimmerman concludes that Spectral AI is making progress toward important milestones and maintains that the stock’s value is likely to increase as these milestones are met.
In other recent news, Spectral AI reported its highest revenue in company history for 2024, with a notable 63.5% increase in R&D revenue, reaching $29.6 million. Gross margins improved to 44.9%, while general and administrative expenses decreased, highlighting effective cost management. BTIG analysts maintained a Buy rating on Spectral AI, setting a price target of $3.00, despite the company’s reported loss per share of $(0.41), which was greater than anticipated. Spectral AI’s guidance for fiscal year 2025 projects revenues of approximately $21.5 million, a 27.3% year-over-year decline, attributed to a slight decrease in R&D revenue. The company is preparing for the FDA submission of its DeepView medical imaging product, targeting clearance in 2026. Spectral AI also plans to spin off its intellectual property subsidiary, Spectral IP, to focus on IP-based financing and monetization strategies. The company’s cash position was bolstered by long-term debt financing and a contract with the Biomedical Advanced Research and Development Authority (BARDA). BTIG analysts highlighted Spectral AI’s progression against key milestones and maintained a positive outlook on the stock’s potential for growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.